Immuno-oncology and immunotherapy Part A

Erscheinungsjahr 2024
ISBN: 978-0-443-29622-2
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm, Gewicht: 490 g

Immuno-Oncology And Immunotherapy - Part A Volume 189, in the Methods in Cell Biology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Specific chapters to this release include, Generation of transmitochondrial cybrids in cancer cells, Methods for flow cytometry analysis for tumor infiltrating cells functions and phenotype, Innovative 2D and 3D methods of tumor cells culture, and more.

Autoren/Hrsg.

Weitere Mitwirkende

Charpentier, Maud

Fachgebiete

• Naturwissenschaften Biowissenschaften Molekularbiologie
• Naturwissenschaften Biowissenschaften Entwicklungsbiologie
• Naturwissenschaften Biowissenschaften Zellbiologie

Inhaltsverzeichnis

1. Assessment of translation rate in leukemic cells and immune cells of the microenvironment by OPP protein synthesis assay

Vanessa Klapp, Ozgu Gumustekin, Jérôme Paggetti, Etienne Moussay and Anne Largeot

2. Generation of transmitochondrial cybrids in cancer cells

Ruth Soler-Agesta, Cristina Ripollés-Yuba, Joaquín Marco-Brualla, Raquel Moreno-Loshuertos, Ai Sato, Manuel Beltrán-Visiedo, Lorenzo Galluzzi and Alberto Anel

3. Enzyme-linked Immunospot (Elispot) assay to quantify peptide-specific IFN-? production by splenocytes in a mouse tumor model after radiation therapy

Benoît Lecoester, Yaoyao Xie, Amélie Marguier, Laura Boulerot, Marine Malfroy, Olivier Adotévi and Jihane Boustani

4. Tumor slice culture system for ex vivo immunotherapy studies

Leire Arrizabalaga, Joan Salvador Russo-Cabrera, Virginia Belsúe, Pedro Berraondo, Ignacio Melero and Fernando Aranda

5. Identification and analysis of alloreactive T lymphocytes from peripheral blood mononuclear cells

Alberto Susana, Giovanni Galletti, Gabriele De Simone, Chiara Camisaschi and Enrico Lugli

6. Assessment of pDCs functional capacity upon exposure to tumor-derived soluble factors

Vladimír Koucký, Linn A. Syding, Klára Placková, Lucie Pavelková and Anna Fialová

7. Degranulation assay to evaluate NK cell natural and antibody-dependent cell-mediated cytotoxicity against A549 tumor spheroids

Ainara Lopez-Pardo, Ainhoa Amarilla-Irusta, Víctor Sandá, Mario Stan, Francisco Borrego and Laura Amo

8. Characterization of Natural Killer cells infiltrating irradiated murine tumors through flow cytometry

Jérémy Baude, Riad Ladjohounlou, Emeric Limagne, Lisa Froidurot, Véronique Morgand and Céline Mirjolet

9. Flow cytometry detection and quantification of circulating leukocyte subpopulations in mice after brain irradiation

Julie Coupey, Marine M. Leblond, Erika S. Hue and Samuel Valable

10. Flow cytometry-assisted analysis of phenotypic maturation markers on an immortalized dendritic cell line

Ginevra Campia, Manuel Beltrán-Visiedo, Ruth Soler-Agesta, Ai Sato, Norma Bloy, Liwei Zhao, Peng Liu, Oliver Kepp, Guido Kroemer, Lorenzo Galluzzi and Claudia Galassi

11. Optimization and intra-assay validation of a multiparametric flow cytometric test for monitoring circulating TREGs

Iole Macchia, Floriana Iacobone and Francesca Urbani

12. Cytofluorometric assessment of calreticulin exposure on CD38+ plasma cells from the human bone marrow

Manuel Beltrán-Visiedo, Alfonso Serrano-Del Valle, Nelia Jiménez-Aldúan, Ruth Soler-Agesta, Javier Naval, Lorenzo Galluzzi and Isabel Marzo

Über Autor(innen)

Charpentier, Maud
Maud Charpentier received her M.Sc. in Cellular Biology and her Ph.D. in Immunology from the University of Nantes, France. She chose to pursue an academic career and continued her postdoctoral training in the United States. She joined the Department of Radiation Oncology at Weill Cornell Medicine under the mentorship of Dr. Sandra Demaria. Maud has a long-standing interest in the anti-tumor immune response and its role in controlling cancer progression and treatment outcomes. Her research focuses on understanding the synergy between radiation therapy and immunotherapy in solid tumors, with the aim of overcoming resistance to treatment and developing innovative therapeutic approaches in preclinical models.